New test aims to match lung cancer patients with best therapy
NCT ID NCT07250477
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This phase 2 trial tests whether using a proteomic test (PROphet CB) and a toxicity assessment (CARG-TT) to guide first-line treatment can improve 12-month survival in people with advanced non-small cell lung cancer. About 56 participants will be randomly assigned to receive either standard care or a personalized treatment plan based on these tests. The goal is to see if this tailored approach leads to better outcomes and fewer severe side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Immune checkpoint inhibitor (ICI) with or without chemotherapy, guided by a proteomic test (PROphet CB) and a toxicity risk assessment (CARG-TT)
What this could lead to
If successful, this approach could help doctors choose the most effective first-line treatment for each patient with advanced lung cancer, potentially improving survival and reducing side effects.
What could go wrong
This is a small, early-phase (phase 2) trial with only 56 participants, so results may not apply to all patients. The proteomic test is new and unproven, and the treatment may not improve outcomes or could cause unexpected side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL-CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of California Davis Comprehensive Cancer Center
RECRUITINGSacramento, California, 95817, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact